Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021
September 25 2024 - 3:00AM
Planegg/Martinsried, September 25, 2024 –
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard),
an oncology platform company focused on the research and
development of T cell receptor (TCR)-guided therapies for the
treatment of cancer, today announced the filing of a new patent
application protecting MDG2021, a T cell receptor engineered T cell
(TCR-T) therapy targeting Kirsten rat sarcoma viral oncogene
homologue (KRAS) G12D with human leukocyte antigen (HLA)-A*11, for
the TCR-T therapy alone as well as in combination with the
Company’s PD1-41BB costimulatory switch protein (CSP) technology to
the European Patent Office. MDG2021 marks the second candidate
within the KRAS library targeting KRAS G12D (HLA-A*11) for which
the Company announced lead selection in June 2024. The addition of
MDG2021 to Company’s KRAS targeting TCR library significantly
impacts the addressable patient population with the combination of
KRAS G12V and KRAS G12D mutations comprising ~50% of all KRAS
mutations in all tumors (pan-cancer), or even >70% in pancreatic
adenocarcinoma. (Yang et al., J Clin Med 2023)
“We are pleased to announce the patent filing
for MDG2021, our optimal affinity 3S (sensitive, specific and safe)
TCR targeting KRAS G12D (HLA-A*11), alone and in combination with
our PD1-41BB armoring and enhancement CSP,” said Selwyn Ho CEO at
Medigene. “This filing reaffirms our commitment to broaden our
intellectual property for TCRs targeting both neoantigens and
cancer testis antigens that have potential utility in multiple
TCR-guided treatment modalities including TCR-T therapies such as
MDG2021, as well as TCR-guided T cell engager therapies (MDG3010)
and TCR-natural killer cell therapies.”
Medigene continually extends and strengthens its
patent portfolio with new technologies and expands existing patents
into additional jurisdictions. The Company maintains 29 different
patent families worldwide covering applications protecting
Medigene’s 3S TCRs as well as its exclusive E2E Platform
technologies.
--- end of press release ---
About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology
platform company dedicated to developing T cell receptor
(TCR)-guided therapies to effectively eliminate cancer. Its
End-to-End Platform generates optimal 3S (sensitive, specific and
safe) T cell receptors with unique and distinctive attributes that
are utilized in multiple therapeutic modalities, such as T cell
receptor engineered T cell (TCR-T) therapies, TCR-guided T cell
engager therapies and TCR-natural killer cell therapies for both
its in-house product pipeline and partnering.
Medigene’s lead TCR-T program MDG1015 is a
potential best-in-class, TCR-T therapy to treat multiple solid
tumor indications. The End-to-End Platform technologies enable
armoring and enhancing of these T cells to overcome the
immunosuppressive tumor microenvironment (TME) and ensure the T
cell drug product composition maximizes safety, efficacy and
durability of response. Medigene’s MDG1015 received IND approval in
Q3 2024 and is filing for CTA in Q4 2024. For more information,
please visit https://medigene.com/
About Medigene’s End-to-End Platform
Medigene’s approach to immunotherapy harnesses
the immense power of natural T cell receptors. By combining these
TCRs with different components of the immune system such as T
cells, natural killer (NK) cells or a CD3 complex (TCE, T cell
engager), highly specific, sensitive and safe modalities are formed
to either complement and/or activate the body’s defense systems
against cancer. Medigene’s comprehensive End-to-End (E2E) Platform
is built on a foundation of proprietary and cutting-edge
technologies, driving the development of highly specific TCR-guided
therapies, including the latest advancements in TCR-T, TCR-NK and
TCR-TCE drug products. The E2E Platform incorporates sophisticated
TCR generation and optimization techniques, such as Allogeneic-HLA
TCR Priming, and integrates advanced product armoring and
enhancement features like PD1-41BB and CD40L-CD28 Costimulatory
Switch Proteins, and iM-TCR. In addition, the E2E Platform offers
solutions to developing optimal cell therapy drug products for
improved safety, efficacy and durability. Collaborations with
partners like BioNTech, Regeneron and WuXi Biologics further
underscore the platform’s capabilities and its potential to
revolutionize cancer treatment.
This press release contains forward-looking
statements representing the opinion of Medigene as of the date of
this release. The actual results achieved by Medigene may differ
significantly from the forward-looking statements made herein.
Medigene is not bound to update any of these forward-looking
statements. Medigene® is a registered trademark of Medigene AG.
This trademark may be owned or licensed in select locations
only.
Medigene AG
Pamela Keck Phone: +49 89 2000 3333 01 E-mail:
investor@medigene.com
In case you no longer wish to receive any
information about Medigene, please inform us by e-mail
(investor@medigene.com). We will then delete your address from our
distribution list.